secwatch.observer — SEC 8-K summary
======================================

Issuer:     AIM ImmunoTech Inc. (AIM)
CIK:        0000946644
Form:       8-K
Filed at:   2026-06-04T13:00:38+00:00
Accession:  0001493152-26-027210
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AIM ImmunoTech highlights Ampligen preclinical data for Ebola preparedness
--------------------------------------------------------------------------

- Video discusses Ampligen as prophylactic/early-onset treatment for Bundibugyo Ebola strain with no approved therapies.
- Preclinical findings: 100% protective survival with early Ampligen administration in lethal Ebola mouse model.
- Ampligen has orphan drug designation from FDA and EMA for Ebola virus disease.
- Updated Ebola-focused corporate presentation available on company website.
- CEO Thomas Equels noted urgent need for therapeutic in ongoing outbreak.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946644/000149315226027210/0001493152-26-027210-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946644/000149315226027210/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-027210

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer